EP Patent

EP3810581A1 — Crystal modifications of odevixibat

Assigned to Albireo AB · Expires 2021-04-28 · 5y expired

What this patent protects

The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7- methylthio-8-(N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)- 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modificatio…

USPTO Abstract

The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7- methylthio-8-(N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)- 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modifications and 2 of odevixibat. The invention also relates toa process for the preparation of crystal modification 1 of odevixibat, toa pharmaceutical composition comprising crystal modification 1, and to the use of this crystal modification in the treatment of various conditionsas described herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP3810581A1
Jurisdiction
EP
Classification
—
Expires
2021-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Albireo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.